Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Empaveli | pegcetacoplan | Paroxysmal nocturnal hemoglobinuria | Reimburse with clinical criteria and/or conditions | Complete | ||
Ultomiris | ravulizumab | Paroxysmal nocturnal hemoglobinuria | Reimburse with clinical criteria and/or conditions | Complete | ||
Soliris | Eculizumab | Paroxysmal nocturnal hemoglobinuria (PNH) | Do not list | Complete | ||
TBC | danicopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Active | |||
TBC | ravulizumab | Paroxysmal nocturnal hemoglobinuria. | Withdrawn | |||
Tafinlar and Mekinist | dabrafenib and trametinib | Pediatric glioma with a BRAF V600E | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Istodax | Romidepsin | Peripheral T-Cell Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Folotyn | Pralatrexate | Peripheral T-Cell Lymphoma (PTCL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Adcetris | Brentuximab Vedotin | peripheral T-cell lymphoma (PTCL) | Reimburse | Complete | ||
Kuvan | Sapropterin dihydrochloride | Phenylketonuria | N/A | Complete |